Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.
Approval Alert | Axatilimab in Pediatric/Adult Chronic GVHD
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
3
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
4
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
5
